The Detection of Cytokines

1. What are Cytokines?

Cytokines are a diverse superfamily of soluble proteins, including interleukins (ILs), interferons (IFNs), tumor necrosis factors (TNFs), colony-stimulating factors (CSFs), chemokines, and growth factors, that mediate cell-cell communication in nearly all biological processes. Produced transiently and in a cell-specific manner in response to environmental stimuli, cytokines act via autocrine, paracrine, and endocrine signaling to regulate immune cell activation, differentiation, proliferation, and apoptosis.

Figure 1. Various cells that produce cytokines

Cytokines exert biological effects by binding to corresponding cytokine receptors on the cell surface. The combination of cytokines and their receptors initiates complex intracellular molecular interactions, ultimately causing changes in cellular gene transcription.

Figure 2. The process by which cytokines work

2. Why Do We Detect Cytokines?

Cytokines are soluble, low-molecular-weight signaling proteins that orchestrate intercellular communication within the immune system, regulating critical processes including inflammation, immune cell maturation, pathogen defense, and tissue homeostasis.

Dysregulation of cytokine signaling is a hallmark of a broad spectrum of human diseases, including rheumatoid arthritis, multiple sclerosis, cancer, sepsis, and neurodegenerative disorders. Under physiological conditions, circulating cytokines are typically present at picomolar to low picogram-per-milliliter concentrations, but their levels can increase up to 1,000-fold during immune activation or pathological dysregulation. As such, the ability to precisely quantify cytokine expression and secretion is indispensable for decoding immune regulatory networks, identifying disease biomarkers, and evaluating the efficacy of immunotherapies and vaccines.

3. Technologies for Cytokine Detection

These foundational methodologies remain the backbone of cytokine research, with well-validated protocols, broad accessibility, and well-defined performance characteristics for routine laboratory use. The best method depends on whether the goal is absolute quantification, multiplex profiling, single-cell resolution, or near-real-time monitoring.

3.1 Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA remains a classic method for cytokine measurement because it is familiar, relatively straightforward, and well-established. It is often used for single-analyte quantification in serum, plasma, or culture supernatants.

The sandwich ELISA is the most common method for cytokine quantification. It uses matched antibody pairs that bind to different epitopes of the target cytokine. The cytokine in the sample is captured by an immobilized antibody, detected by a second antibody, and then measured through an enzyme-conjugated antibody and colorimetric or chemiluminescent signal readout. The signal intensity, quantified against a standard curve, is proportional to the cytokine concentration.

Figure 3. Sandwich ELISA (Indiect)

• Core Advantages: High specificity, wide commercial availability for nearly all human and murine cytokines, simple workflow, and low technical barrier to entry. Standard sandwich ELISA has a linear dynamic range of ~1–2 orders of magnitude, with a limit of detection (LOD) typically in the low pg/mL range ^[1][2].
• Limitations: Single-plex detection (measures one cytokine per well), relatively large sample volume requirement (50~100 μL per analyte), and lower throughput ^[1][5].
• Modified ELISA Formats:

  - Chemiluminescent ELISA: Replaces colorimetric substrates with chemiluminescent reagents, improving LOD by 10–100 fold compared to colorimetric ELISA ^[2].

  - Electrochemical ELISA: Uses electrochemical signal transduction, enabling miniaturization and point-of-care (POC) applications ^[6].

3.2 Multiplex Immunoassays

Given that cytokines act in complex, interconnected networks, multiplex methods that simultaneously quantify dozens of cytokines in a single small-volume sample have become foundational for translational and clinical research.

3.2.1 Bead-Based Multiplex Immunoassays

These assays use spectrally encoded microspheres (beads) conjugated to cytokine-specific capture antibodies. Each bead population has a unique fluorescent signature, enabling target differentiation in a single reaction. After incubation with the sample and fluorophore-labeled detection antibodies, bead fluorescence is quantified via flow cytometry or dedicated analyzers ^[1][2].

• Leading Commercial Platforms:

  - Luminex xMAP Technology: Supports up to 100 analytes per well, with a sample volume requirement of 25–50 μL, and a 3–4 order of magnitude linear dynamic range ^[1][7].

  - Cytometric Bead Array (CBA): Compatible with standard laboratory flow cytometers, lowering the barrier to entry for multiplex cytokine analysis ^[2][7].

  - One-Step Flow Cytometry-Based Multiplex Assays: Lyophilized, room-temperature-stable reagent mixes that reduce assay time and cold-chain requirements, validated on clinical serum samples from patients with infectious diseases ^[3].

• Key Advantages: High throughput, minimal sample consumption, and ability to profile entire cytokine networks in parallel ^[1][2][7].
• Limitations: Potential for antibody cross-reactivity, higher inter-assay variability than ELISA, and inconsistent absolute concentration values across different platforms ^[1][5].

3.2.2 Planar Antibody Microarrays

Microarrays use spatially patterned capture antibodies printed on glass or membrane slides, enabling simultaneous detection of up to hundreds of cytokines in a single sample. Signal detection is typically via fluorescence or chemiluminescence, with dedicated scanners for quantification ^[1][2].

• Applications: Discovery-phase cytokine biomarker screening in biobank samples, with low sample volume requirements (10–15 μL) ^[2].
• Limitations: Lower quantitative accuracy than bead-based assays, higher susceptibility to matrix effects, and limited use for absolute quantification in clinical settings ^[1][5].

3.3 Single-Cell Cytokine Detection Techniques

Bulk cytokine detection methods cannot resolve cellular heterogeneity, which is critical for identifying rare cytokine-producing cell populations (e.g., antigen-specific T cells) in immune monitoring. The following methods enable single-cell resolution cytokine analysis ^[1][2].

3.3.1 Enzyme-Linked Immunospot (ELISPOT) and FluoroSpot Assay

ELISPOT is the gold-standard method for quantifying the frequency of cytokine-secreting cells at the single-cell level. The assay uses capture antibodies coated on a microplate well to trap cytokines secreted by individual live cells cultured on the plate. Captured cytokines are then detected by enzyme-conjugated secondary antibodies, forming visible spots that correspond to individual cytokine-producing cells ^[1][2].

• FluoroSpot: A modified version that uses fluorophore-labeled detection antibodies instead of enzyme conjugates, enabling simultaneous detection of 2–4 cytokines from the same single cell ^[2].
• Key Advantages: Extremely high sensitivity (can detect a single cytokine-secreting cell per million cells), quantitative measurement of secretion frequency, and compatibility with high-throughput screening ^[1][2].
• Applications: Vaccine efficacy testing, antigen-specific T cell response monitoring, and immune cell functional characterization ^[2].

3.3.2 Flow Cytometric Intracellular Cytokine Staining (ICS)

ICS combines flow cytometry with immunofluorescent staining to detect cytokines inside fixed and permeabilized cells, enabling simultaneous measurement of cytokine production and cell surface immunophenotype markers (e.g., CD4, CD8) at the single-cell level ^[1][2].

• Key Advantages: Multi-parameter profiling (can link cytokine production to specific immune cell subsets), high throughput, and compatibility with polychromatic panels to detect multiple cytokines per cell ^[2].
• Limitations: Requires cell fixation (kills cells, preventing downstream functional analysis) and use of protein transport inhibitors (e.g., brefeldin A, monensin) to retain cytokines intracellularly, which may alter cellular physiology ^[1][2].

3.4 Ultrasensitive Single-Molecule Cytokine Detection Technologies

Conventional immunoassays lack the sensitivity to detect low, homeostatic cytokine concentrations in healthy individuals, which are critical for establishing baseline levels and early disease detection. Ultrasensitive technologies achieve LODs in the sub-pg/mL to fg/mL range by counting single cytokine molecules digitally ^[2][5].

3.4.1 Single Molecule Array (Simoa)

Simoa is a digital ELISA platform that uses antibody-conjugated magnetic microbeads to capture cytokines, followed by immunocomplex formation with enzyme-labeled detection antibodies. Individual beads are isolated in femtoliter-scale microwells, where fluorogenic substrate hydrolysis generates a fluorescent signal in wells containing a single target cytokine molecule ^[2][5].

• Performance: Achieves LODs down to the sub-fg/mL range, ~1000-fold more sensitive than conventional ELISA ^[1][5].
• Applications: Detection of ultra-low-abundance cytokines in cerebrospinal fluid, serum, and plasma for neurodegenerative disease and early cancer biomarker research ^[2][5].

3.4.2 Other Ultrasensitive Platforms

• MSD S-plex: Meso Scale Discovery's electrochemiluminescence-based platform, validated as the most sensitive multiplex cytokine assay in head-to-head comparisons, with superior performance to Olink Target 48 and Quanterix SP-X for clinical serum and plasma samples ^[5].
• Single Molecule Counting (SMC): Uses laser confocal microscopy to count single fluorescently labeled cytokine molecules, with sub-pg/mL LODs for multiplexed cytokine detection ^[2][5].
• Immuno-PCR: Combines antibody-based cytokine capture with PCR amplification of a DNA barcode conjugated to the detection antibody, achieving ultra-high sensitivity via nucleic acid amplification ^[1][2].

3.5 Nucleic Acid-Based Cytokine Expression Detection

These methods indirectly measure cytokine production by quantifying cytokine mRNA transcripts, providing insights into cellular cytokine gene expression rather than secreted protein levels [1][2].

3.5.1 Quantitative Real-Time PCR (qRT-PCR)

qRT-PCR is the standard method for quantifying cytokine mRNA expression in cell or tissue samples, using reverse transcription to convert cytokine mRNA to cDNA, followed by real-time PCR amplification and fluorescence-based quantification ^[1][2].

• Advantages: High sensitivity, wide dynamic range, and ability to detect low-abundance cytokine transcripts from small cell numbers ^[2].
• Limitations: mRNA levels do not always correlate with secreted protein levels (due to post-transcriptional and post-translational regulation), and cannot distinguish between intracellular and secreted cytokine protein ^[1][2].

3.5.2 Single-Cell RNA Sequencing (scRNA-seq)

scRNA-seq enables transcriptome-wide profiling of cytokine gene expression at the single-cell level, resolving the cellular heterogeneity of cytokine production in complex immune cell populations ^[2].

• Applications: Mapping cytokine expression landscapes in the tumor microenvironment, inflammatory tissues, and infectious disease settings ^[2].
• Limitations: High cost, technical complexity, and the same disconnect between mRNA and protein levels as bulk qRT-PCR ^[1][2].

3.6 Mass Spectrometry-Based Cytokine Detection

Mass spectrometry (MS) methods enable antibody-independent, label-free detection and quantification of cytokines, with the ability to simultaneously measure cytokine isoforms, post-translational modifications, and degradation products ^[2][4].

Key Approaches:

• Multiple Reaction Monitoring (MRM): A targeted MS method that uses triple-quadrupole instruments to quantify specific cytokine peptides, with LODs in the low attomol/μL range and high reproducibility (median coefficient of variation <2.5%) ^[9].
• Shotgun Proteomics: Untargeted MS for global secretome profiling, used for the discovery of novel cytokine biomarkers in disease settings ^[4].
• Advantages: High specificity, no antibody cross-reactivity, and ability to characterize cytokine proteoforms ^[2][4][9].
• Limitations: Lower sensitivity than immunoassays for most cytokines, high instrument cost, and technical expertise requirements, limiting routine clinical use ^[1][2][4].

4. Emerging Biosensing Technologies for Cytokine Detection

Conventional cytokine detection methods are largely limited to centralized laboratory settings, requiring bulky instrumentation, specialized expertise, long turnaround times, and large sample volumes ^[1][2][6]. Emerging biosensing technologies integrate nanomaterial engineering, microfluidics, and molecular tools to transduce cytokine binding events into quantifiable signals, enabling rapid, miniaturized, POC, and continuous cytokine detection with ultra-high sensitivity and minimal sample consumption ^[2][6][10].

4.1 Electrochemical Biosensors

Electrochemical biosensors are the most clinically advanced emerging cytokine detection platform, converting cytokine-antibody/aptamer binding into measurable electrical signals (amperometric, voltammetric, impedimetric) via a sandwich immunoassay format on a functionalized electrode surface ^[10][11].

• Key Applications: POC sepsis diagnosis, real-time CRS monitoring in CAR-T therapy, and multiplex cytokine profiling in resource-limited settings ^[11][20].
• Core Advantages: Ultra-high sensitivity (LOD down to fg/mL range), rapid results (5–30 minutes), compatibility with handheld POC devices, and resistance to optical interference from turbid samples such as whole blood ^[5][10][11].
• Limitations: Risk of non-specific matrix adsorption to electrodes, variable long-term stability of immobilized capture probes, and higher inter-assay variability than ELISA ^[10][11].

4.2 Optical Biosensors

Optical biosensors detect cytokines by measuring light property changes induced by target binding to immobilized capture probes, with surface plasmon resonance (SPR), localized SPR (LSPR), and surface-enhanced Raman scattering (SERS) as the dominant modalities ^[7][12][13].

• SPR/LSPR: Label-free, real-time detection via refractive index changes at the metal-solution interface, enabling kinetic analysis of cytokine-antibody binding. Advanced platforms achieve fg/mL LOD for key cytokines, with SPR imaging (SPRi) supporting multiplexed detection ^[12][13].
• SERS: Leverages 10¹⁰–10¹⁵ fold signal enhancement from plasmonic nanostructures, achieving attomolar-level sensitivity and exceptional multiplexing capability via unique Raman reporter nanotags ^[13][26]. This technology has been clinically validated for predicting and monitoring immune toxicities in cancer immunotherapy via single-molecule cytokine profiling ^[13].
• Key Applications: Therapeutic antibody development, intraoperative inflammation monitoring, and high-sensitivity cytokine biomarker discovery ^[12][26].
• Limitations: Susceptibility to matrix effects, high instrument cost for traditional SPR systems, and batch-to-batch variability of SERS substrates ^[12][13].

4.3 Field-Effect Transistor (FET) Biosensors

FET biosensors are label-free electrical platforms that transduce cytokine binding directly into current changes via a semiconductor channel functionalized with capture probes ^[17].

• Key Applications: Continuous real-time cytokine monitoring in critically ill patients, ultra-sensitive detection in limited-volume samples (e.g., cerebrospinal fluid), and wearable sensor integration ^[17][20].
• Core Advantages: Ultra-fast response (seconds to 5 minutes), ultra-high sensitivity (LOD down to aM range), label-free real-time detection, and compatibility with CMOS fabrication for miniaturized devices ^[17]. Silicon nanowire FET platforms, for example, have achieved reliable IL-6 detection down to 2.1 pg/mL, covering the clinical range for predicting severe COVID-19 outcomes ^[17].
• Limitations: High susceptibility to pH and ionic strength interference in biological samples, poor long-term stability in biofluids, and limited multiplexing capability ^[17].

4.4 Microfluidic-Integrated Biosensing Systems

Microfluidic "lab-on-a-chip" platforms integrate cytokine detection with microscale fluidic control, automating all assay steps (sample processing, incubation, detection) on a single chip ^[14].

• Key Applications: POC testing in emergency and low-resource settings, single-cell immune heterogeneity profiling, and integration with wearable sensing systems ^[14][11].
• Core Advantages: Minimal sample consumption (1–50 μL), full workflow automation, integrated upstream sample processing (e.g., plasma separation from whole blood), and compatibility with single-cell cytokine analysis [14]. These systems have been validated for rapid cytokine storm profiling in COVID-19 patients and dynamic monitoring of cytokine secretion from single immune cells ^[14].
• Limitations: Complex microfabrication increases production costs, risk of bubble formation and channel clogging, and limited compatibility with large-volume samples ^[14].

4.5 Paper-Based and Wearable POC Biosensors

These platforms address the need for low-cost, accessible cytokine monitoring outside centralized labs, with two core formats:

• Paper-based biosensors: Use cellulose paper and capillary flow to run sandwich immunoassays, with colorimetric or electrochemical readout. They offer ultra-low cost, simple operation, and biodegradability, making them ideal for large-scale screening in low-resource settings ^[15][21].
• Wearable biosensors: Flexible, skin-mounted devices that non-invasively detect cytokines in sweat, interstitial fluid, or tear fluid, enabling real-time continuous inflammatory status monitoring. Validated devices show >90% accuracy for key cytokines (IL-6, TNF-α, IL-8, IL-10), with readings highly correlated to matched serum levels ^[16][22][25].
• Key Applications: Large-scale inflammatory disease screening, chronic inflammation monitoring in rheumatoid arthritis and inflammatory bowel disease, and non-invasive infection monitoring ^[16][21][25].
• Limitations: Lower quantitative accuracy for paper-based colorimetric devices, variable sweat cytokine secretion rates for wearables, and limited long-term stability of capture probes ^[15][22].

4.6 CRISPR-Enhanced Ultrasensitive Biosensors

CRISPR-enhanced platforms leverage the collateral cleavage activity of Cas12a/Cas13a systems to amplify cytokine binding signals, combining antibody-based capture with CRISPR-mediated signal amplification ^[18][24].

• Key Applications: Early cancer detection via plasma cytokine biomarker profiling, ultra-sensitive detection in limited-volume clinical samples, and POC cytokine storm detection ^[19][20][24].
• Core Advantages: Ultra-high sensitivity (LOD down to fg/mL range, 100–1000-fold higher than conventional ELISA), dual recognition specificity from antibody binding and CRISPR sequence detection, and compatibility with standard lab equipment and POC integration ^[18][19][24]. A clinically validated CRISPR-ELISA assay identified a 3-cytokine panel for early lung cancer detection with 80.6% sensitivity and 82.0% specificity ^[18].
• Limitations: Complex multi-step workflow, strict RNase-free requirements for Cas13a-based assays, and high reagent costs ^[18][24].

Conclusion

Cytokine detection has moved from simple single-analyte measurement to multiplex, single-cell, and digital profiling. Each technology has distinct advantages and limitations, and the optimal detection strategy depends on the research question, sample type, required sensitivity, and multiplexing capacity.

For researchers, the best approach is to match the method to the biological question. For clinicians and translational teams, the next step is to turn cytokine data into reliable, standardized, and actionable information.

As technology continues to advance, cytokine detection will become increasingly sensitive, high-throughput, and physiologically relevant, enabling unprecedented insights into cytokine signaling networks and the development of novel cytokine-targeted therapeutics for a broad spectrum of human diseases.